eloralintide (LY3841136) / Eli Lilly - LARVOL DELTA

A Study of Eloralintide (LY3841136) in Participants With Different Levels of Liver Damage and in Participants With Healthy Livers. (clinicaltrials.gov) - P1 | N=36 | Recruiting | Sponsor: Eli Lilly and Company | Not yet recruiting ➔ Recruiting

Enrollment open • Hepatitis C • Hepatology • Liver Failure

J3R-MC-YDAO: A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight (ENLIGHTEN-3) (clinicaltrialsregister.eu) - P2/3 | N=85 | Not yet recruiting | Sponsor: Eli Lilly & Co.

New P2/3 trial • Genetic Disorders • Obesity • Obstructive Sleep Apnea • Respiratory Diseases • Sleep Apnea • Sleep Disorder

Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes. (PubMed, Peptides) - "The first therapeutically useful amylin receptor (AMYR) agonist, pramlintide was based upon the structure of non-aggregating rat amylin and found limited application as an adjunct to insulin therapy...Amongst these agents is the dual AMYR/ calcitonin-receptor (CTR) agonist, cagrilintide that has also been co-formulated into a once weekly subcutaneous injection with the long-acting glucagon-like peptide-1receptor (GLP-1R) agonist, semaglutide (CagriSema)...Several recently developed long-acting amylin analogues have shown strong efficacy as monotherapy in clinical trials: these include eloralintide, petrelintide, Met-233 and AZD6234...Gastrointestinal side effects, especially nausea, similar to those reported for GLP-1R agonists are commonplace during initiation and up-titration of amylin analogues but mostly resolve during continued use. Evidence is emerging that long-acting AMYR agonists may show potential therapeutic benefits in treatment of patients with fatty liver..."

Journal • Review • Cardiovascular • Diabetes • Genetic Disorders • Hepatology • Hypertension • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function (clinicaltrials.gov) - P1 | N=28 | Recruiting | Sponsor: Eli Lilly and Company | Not yet recruiting ➔ Recruiting

Enrollment open • Chronic Kidney Disease • Nephrology • Renal Disease

ENLIGHTEN-1: A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes (clinicaltrials.gov) - P3 | N=1980 | Recruiting | Sponsor: Eli Lilly and Company | Not yet recruiting ➔ Recruiting

Enrollment open • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

ENLIGHTEN-3: A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight (clinicaltrials.gov) - P3 | N=800 | Recruiting | Sponsor: Eli Lilly and Company | Not yet recruiting ➔ Recruiting

Enrollment open • Genetic Disorders • Obesity • Obstructive Sleep Apnea • Respiratory Diseases • Sleep Apnea • Sleep Disorder

ENLIGHTEN-4: Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight (clinicaltrials.gov) - P3 | N=900 | Recruiting | Sponsor: Eli Lilly and Company | Not yet recruiting ➔ Recruiting

Enrollment open • Genetic Disorders • Immunology • Musculoskeletal Pain • Obesity • Osteoarthritis • Pain • Rheumatology

A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function (clinicaltrials.gov) - P1 | N=28 | Not yet recruiting | Sponsor: Eli Lilly and Company

New P1 trial • Chronic Kidney Disease • Nephrology • Renal Disease

ENLIGHTEN-6: A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin (clinicaltrials.gov) - P3 | N=900 | Not yet recruiting | Sponsor: Eli Lilly and Company

New P3 trial • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

ENLIGHTEN-6: A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin (clinicaltrials.gov) - P3 | N=900 | Recruiting | Sponsor: Eli Lilly and Company | Not yet recruiting ➔ Recruiting

Enrollment open • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

A Study of Eloralintide (LY3841136) in Participants With Different Levels of Liver Damage and in Participants With Healthy Livers. (clinicaltrials.gov) - P1 | N=36 | Not yet recruiting | Sponsor: Eli Lilly and Company

New P1 trial • Hepatitis C • Hepatology • Liver Failure

Eli Lilly and Company has launched a large phase 3 program to test eloralintide (LY3841136) in adults with moderate to severe obstructive sleep apnea who are also obese or overweight. (TipRanks) - "The main goal is to see whether a once-weekly drug can safely reduce sleep apnea severity in two key patient groups and potentially offer a more convenient option than current standard equipment-based treatments."

Trial status • Obesity • Obstructive Sleep Apnea

ENLIGHTEN-3: A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight (clinicaltrials.gov) - P3 | N=800 | Not yet recruiting | Sponsor: Eli Lilly and Company

New P3 trial • Genetic Disorders • Obesity • Obstructive Sleep Apnea • Respiratory Diseases • Sleep Apnea • Sleep Disorder

A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity (clinicaltrials.gov) - P1 | N=188 | Completed | Sponsor: Eli Lilly and Company | Active, not recruiting ➔ Completed

Trial completion • Genetic Disorders • Obesity

Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept. (PubMed, Diabetes Obes Metab) - "Eloralintide once weekly was well tolerated with minimal gastrointestinal adverse events and resulted in clinically meaningful weight loss."

Journal • P1 data • Fatigue • Genetic Disorders • Infectious Disease • Novel Coronavirus Disease • Obesity • Pain

A Study of LY3841136 in Japanese Participants With Obesity or Overweight (clinicaltrials.gov) - P1 | N=128 | Completed | Sponsor: Eli Lilly and Company | Active, not recruiting ➔ Completed

Monotherapy • Trial completion • Genetic Disorders • Obesity

ENLIGHTEN-4: Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight (clinicaltrials.gov) - P3 | N=900 | Not yet recruiting | Sponsor: Eli Lilly and Company

New P3 trial • Genetic Disorders • Immunology • Musculoskeletal Pain • Obesity • Osteoarthritis • Pain • Rheumatology

ENLIGHTEN-1: A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes (clinicaltrials.gov) - P3 | N=1980 | Not yet recruiting | Sponsor: Eli Lilly and Company

New P3 trial • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Eli Lilly Completes Phase 1 Study of Eloralintide for Obesity in China (TipRanks) - "The study began on April 1, 2025, and was completed with the last update submitted on November 18, 2025."

Trial completion • Obesity

ENLIGHTEN-2: A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes (clinicaltrials.gov) - P3 | N=1035 | Recruiting | Sponsor: Eli Lilly and Company | Not yet recruiting ➔ Recruiting

Enrollment open • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

ENLIGHTEN-2: A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes (clinicaltrials.gov) - P3 | N=1035 | Not yet recruiting | Sponsor: Eli Lilly and Company

New P3 trial • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity (clinicaltrials.gov) - P1 | N=204 | Active, not recruiting | Sponsor: Eli Lilly and Company | Recruiting ➔ Active, not recruiting

Enrollment closed • Genetic Disorders • Obesity

A Study of Eloralintide (LY3841136) in Chinese Participants With Obesity or Overweight (clinicaltrials.gov) - P1 | N=30 | Completed | Sponsor: Eli Lilly and Company | Active, not recruiting ➔ Completed

Trial completion • Genetic Disorders • Obesity

Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial. (PubMed, Lancet) - P2 | "Eloralintide produced clinically meaningful, dose-dependent reductions in bodyweight over 48 weeks and was generally well tolerated, supporting eloralintide's potential use for obesity treatment."

Journal • P2 data • Diabetes • Fatigue • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Scientific Basis of Amylin Agonism in the Treatment of Obesity and Weight Management (OBESITY WEEK 2025) - "Background: This presentation will provide the scientific background of amylin as well as introduce eloralintide, a selective long-acting, once-weekly amylin receptor agonist under development for weight management... Hence, amylin seems to affect caloric intake by various modes of action."

Genetic Disorders • Metabolic Disorders • Obesity • LEP